However, β2M has been found to be elevated in multiple myeloma, lymphoma, and prostate cancer patients and is a prognostic marker (Mink et al., 2008; Koelzer et al., 2012; Miyashita et al., 2015). The gene discussed is B2M; the disease is prostate carcinoma.